Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD.

(ROG)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
08/12/2019 08/13/2019 08/14/2019 08/15/2019 08/16/2019 Date
272.2(c) 274.3(c) 269.35(c) 268.95(c) 273.2(c) Last
1 362 169 1 957 149 1 845 284 1 515 093 1 625 715 Volume
+0.04% +0.77% -1.80% -0.15% +1.58% Change
More quotes
Financials (CHF)
Sales 2019 61 050 M
EBIT 2019 21 615 M
Net income 2019 14 389 M
Debt 2019 3 719 M
Yield 2019 3,32%
Sales 2020 61 901 M
EBIT 2020 22 229 M
Net income 2020 14 679 M
Finance 2020 4 057 M
Yield 2020 3,45%
P/E ratio 2019 16,9x
P/E ratio 2020 16,3x
EV / Sales2019 3,89x
EV / Sales2020 3,71x
Capitalization 234 B
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists... 
Sector
Pharmaceuticals
Calendar
09/04Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
08/16FDA approves Roche's RozlytrekTM (entrectinib) for people with ROS1-positive,..
GL
08/15Genentech Receives FDA Accelerated Approval for Cancer Treatment
DJ
08/15ROCHE : FDA Approves Genentech's Rozlytrek (entrectinib) for People With ROS1-Po..
BU
08/12NOVARTIS : Sandoz to Appeal Erelzi Patent Case in US
DJ
08/08Bayer buys BlueRock in $600 million bet on stem cell therapies
RE
08/05ROCHE : Andrew Plank appointed President and General Manager of Roche Diagnostic..
AQ
08/05Roche's Tecentriq plus platinum-based chemotherapy reduced the risk of diseas..
GL
08/05GENENTECH : 's Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduce..
BU
08/01Blue-blooded crabs at heart of pharma dispute on drug testing
RE
07/31SPARK THERAPEUTICS : Roche, Spark extend $4.3 billion takeover again, this time ..
RE
More news
Analyst Recommendations on ROCHE HOLDING LTD.
More recommendations
Sector news : Pharmaceuticals - NEC
08/16ABBVIE : Gets FDA OK for Rheumatoid Arthritis Drug Rinvoq
DJ
08/16CELGENE : FDA Grants Approval to Celgene's Impact for Bone Marrow Disorder Treat..
DJ
08/16ALLERGAN : Form 8.3 - Allergan Plc
DJ
08/16NOVO NORDISK : contests Danish lawsuit claiming $1.75 billion
RE
08/16Correction to AstraZeneca's Lynparza Clinical Trial Article on Wednesday
DJ
More sector news : Pharmaceuticals - NEC
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 294,77  CHF
Last Close Price 273,20  CHF
Spread / Highest target 30,3%
Spread / Average Target 7,90%
Spread / Lowest Target -26,8%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.12.24%235 575
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
NOVARTIS17.81%202 958
PFIZER-21.01%190 711